Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TBPH Stock Forecast 2026-2027
$16.62
Current Price
$855.81M
Market Cap
Buy 3
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to TBPH Price Targets
+26.4%
To High Target of $21.00
+2.3%
To Median Target of $17.00
-9.7%
To Low Target of $15.00
TBPH Price Momentum
-0.1%
1 Week Change
+16.0%
1 Month Change
+78.5%
1 Year Change
-11.2%
Year-to-Date Change
-21.0%
From 52W High of $21.03
+99.5%
From 52W Low of $8.33
📊 TOP ANALYST CALLS
Did TBPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Theravance is one of their latest high-conviction picks.
Latest TBPH Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, TBPH has a neutral consensus with a median price target of $17.00 (ranging from $15.00 to $21.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $16.62, the median forecast implies a 2.3% upside. This outlook is supported by 3 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 26.4% upside. Conversely, the most conservative target is provided by Marc Frahm at TD Cowen, suggesting a 9.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TBPH Analyst Ratings
3
Buy
3
Hold
0
Sell
TBPH Price Target Range
Low
$15.00
Average
$17.00
High
$21.00
Current: $16.62
Latest TBPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TBPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 7, 2026 | B. Riley Securities | Mayank Mamtani | Neutral | Maintains | $17.00 |
| Mar 23, 2026 | TD Cowen | Marc Frahm | Hold | Maintains | $15.00 |
| Mar 20, 2026 | BTIG | Julian Harrison | Buy | Reiterates | $21.00 |
| Mar 5, 2026 | Oppenheimer | Trevor Allred | Perform | Downgrade | $N/A |
| Mar 4, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $15.00 |
| Mar 4, 2026 | B. Riley Securities | Mayank Mamtani | Neutral | Downgrade | $14.00 |
| Mar 3, 2026 | BTIG | Julian Harrison | Buy | Maintains | $21.00 |
| Mar 2, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $27.00 |
| Feb 3, 2026 | BTIG | Julian Harrison | Buy | Reiterates | $40.00 |
| Dec 3, 2025 | Oppenheimer | Trevor Allred | Outperform | Initiates | $27.00 |
| Nov 26, 2025 | BTIG | Julian Harrison | Buy | Maintains | $40.00 |
| Nov 11, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $20.00 |
| Sep 12, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Initiates | $28.00 |
| Jun 27, 2025 | BTIG | Julian Harrison | Buy | Maintains | $25.00 |
| Jun 17, 2025 | Jones Trading | Debanjana Chatterjee | Buy | Initiates | $24.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $15.00 |
| Feb 25, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $15.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $15.00 |
| Aug 6, 2024 | Leerink Partners | David Risinger | Market Perform | Downgrade | $10.00 |
| Aug 6, 2024 | TD Cowen | Marc Frahm | Hold | Maintains | $9.00 |
Theravance Biopharma Inc. (TBPH) Competitors
The following stocks are similar to Theravance based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TBPH
Theravance Biopharma
mkt cap
887.22M
Theravance Biopharma Inc. (TBPH) Financial Data
Theravance Biopharma Inc. has a market capitalization of $855.81M with a P/E ratio of 8.4x. The company generates $107.46M in trailing twelve-month revenue with a 98.5% profit margin.
Revenue growth is +144.7% quarter-over-quarter, while maintaining an operating margin of +43.6% and return on equity of +44.8%.
Valuation Metrics
Market Cap
$855.81M
Enterprise Value
$614.57M
P/E Ratio
8.4x
PEG Ratio
0.0x
Price/Sales
8.3x
Growth & Margins
Revenue Growth (YoY)
+144.7%
Gross Margin
N/A
Operating Margin
+43.6%
Net Margin
+98.5%
EPS Growth
+144.7%
Financial Health
Cash/Price Ratio
+36.8%
Current Ratio
10.9x
Debt/Equity
14.4x
ROE
+44.8%
ROA
-0.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Theravance Biopharma Inc. (TBPH) Business Model
About Theravance Biopharma Inc.
What They Do
Develops innovative therapies for respiratory and inflammatory diseases.
Business Model
Theravance Biopharma generates revenue primarily through the commercialization of its flagship product YUPELRI for COPD treatment. The company also advances a diverse clinical pipeline, aiming to secure approval and market access for additional therapies, which can enhance its revenue streams. Strategic partnerships and collaborations further bolster its development efforts and profitability potential.
Additional Information
With a focus on respiratory diseases, inflammatory conditions, and rare disorders, Theravance Biopharma maintains a strong research capability and operates globally from its headquarters in South San Francisco and offices in Dublin. The company is actively involved in clinical trials, seeking to expand its portfolio of FDA-approved treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
97
CEO
Mr. Rick E. Winningham M.B.A.
Country
United States
IPO Year
2014
Website
www.theravance.comTheravance Biopharma Inc. (TBPH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Theravance Stock Declines Around 17% in Three Months: Here's Why
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
Apr 16, 2026
By Zacks Equity Research
Analyst Blog
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Apr 15, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Theravance Biopharma reported declining R&D costs after completing CYPRESS enrollment, despite a 26% loss for shareholders following the Phase 3 trial failure on March 3, 2026.
Why It Matters
Declining R&D costs may signal better financial management, potentially stabilizing future performance, but the recent trial failure severely impacts investor confidence and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of Theravance Biopharma, Inc. (NASDAQ: TBPH). Interested parties can contact Danielle Peyton for more information.
Why It Matters
Theravance Biopharma faces an investigation, potentially signaling legal troubles that could impact stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores can guide investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
The Zacks Style Scores highlight stocks with strong potential, guiding investors towards selections that may outperform the market, impacting portfolio performance positively.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
TBPH shares have dropped due to the failure of its lead drug in a late-stage study, necessitating a pipeline overhaul and increasing uncertainty about the company's future.
Why It Matters
TBPH's failed drug trial leads to a pipeline overhaul, increasing risk and uncertainty, which can negatively impact share value and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Theravance Biopharma, Inc. ($TBPH) is under a fraud investigation, and investors have the opportunity to join the inquiry led by the Schall Law Firm.
Why It Matters
The announcement signals potential legal issues for Theravance Biopharma, which may impact stock value and investor confidence, leading to increased volatility in $TBPH shares.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Zacks Medical-Drugs industry is experiencing peak innovation, with INDV, CPRX, TBPH, RLMD, and AVTX suggested as potential portfolio additions.
Why It Matters
Peak innovation in the Zacks Medical-Drugs industry suggests potential growth and investment opportunities in companies like INDV, CPRX, TBPH, RLMD, and AVTX.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About TBPH Stock
What is Theravance Biopharma Inc.'s (TBPH) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Theravance Biopharma Inc. (TBPH) has a median price target of $17.00. The highest price target is $21.00 and the lowest is $15.00.
Is TBPH stock a good investment in 2026?
According to current analyst ratings, TBPH has 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TBPH stock?
Wall Street analysts predict TBPH stock could reach $17.00 in the next 12 months. This represents a 2.3% increase from the current price of $16.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Theravance Biopharma Inc.'s business model?
Theravance Biopharma generates revenue primarily through the commercialization of its flagship product YUPELRI for COPD treatment. The company also advances a diverse clinical pipeline, aiming to secure approval and market access for additional therapies, which can enhance its revenue streams. Strategic partnerships and collaborations further bolster its development efforts and profitability potential.
What is the highest forecasted price for TBPH Theravance Biopharma Inc.?
The highest price target for TBPH is $21.00 from Julian Harrison at BTIG, which represents a 26.4% increase from the current price of $16.62.
What is the lowest forecasted price for TBPH Theravance Biopharma Inc.?
The lowest price target for TBPH is $15.00 from Marc Frahm at TD Cowen, which represents a -9.7% decrease from the current price of $16.62.
What is the overall TBPH consensus from analysts for Theravance Biopharma Inc.?
The overall analyst consensus for TBPH is neutral. Out of 13 Wall Street analysts, 3 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are TBPH stock price projections?
Stock price projections, including those for Theravance Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:56 AM UTC